CL2020003340A1 - Derivados de la piridopirimidinona para uso como inhibidores de axl. - Google Patents

Derivados de la piridopirimidinona para uso como inhibidores de axl.

Info

Publication number
CL2020003340A1
CL2020003340A1 CL2020003340A CL2020003340A CL2020003340A1 CL 2020003340 A1 CL2020003340 A1 CL 2020003340A1 CL 2020003340 A CL2020003340 A CL 2020003340A CL 2020003340 A CL2020003340 A CL 2020003340A CL 2020003340 A1 CL2020003340 A1 CL 2020003340A1
Authority
CL
Chile
Prior art keywords
pyridopyrimidinone
derivatives
axl
inhibitors
present
Prior art date
Application number
CL2020003340A
Other languages
English (en)
Inventor
Jung-Ho Kim
Jang-Sik Choi
Hee Kyu Lee
Dong-Sik Jung
Sung-Ho Park
Yung-Geun Choi
Original Assignee
Oscotec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscotec Inc filed Critical Oscotec Inc
Publication of CL2020003340A1 publication Critical patent/CL2020003340A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente patente de invención está relacionada principalmente con derivados de la piridopirimidinona para uso como inhibidores de Axl.
CL2020003340A 2018-06-27 2020-12-21 Derivados de la piridopirimidinona para uso como inhibidores de axl. CL2020003340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862690620P 2018-06-27 2018-06-27

Publications (1)

Publication Number Publication Date
CL2020003340A1 true CL2020003340A1 (es) 2021-04-23

Family

ID=68987456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003340A CL2020003340A1 (es) 2018-06-27 2020-12-21 Derivados de la piridopirimidinona para uso como inhibidores de axl.

Country Status (16)

Country Link
US (1) US12350272B2 (es)
EP (1) EP3814350A4 (es)
JP (1) JP7200453B2 (es)
KR (1) KR102698500B1 (es)
CN (1) CN112351985B (es)
AU (1) AU2019292207B2 (es)
BR (1) BR112020026641A2 (es)
CA (1) CA3103160C (es)
CL (1) CL2020003340A1 (es)
EA (1) EA202190125A1 (es)
IL (1) IL279593A (es)
MX (1) MX2020013805A (es)
MY (1) MY204443A (es)
SG (1) SG11202013029UA (es)
WO (1) WO2020004938A1 (es)
ZA (1) ZA202100140B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5940669A (en) 1997-07-03 1999-08-17 Output Technology Corporation Printer
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
MX2012004846A (es) * 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
US8877763B2 (en) * 2012-03-22 2014-11-04 Genosco Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
WO2014045029A1 (en) * 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors

Also Published As

Publication number Publication date
CN112351985A (zh) 2021-02-09
US12350272B2 (en) 2025-07-08
MX2020013805A (es) 2021-03-09
MY204443A (en) 2024-08-28
ZA202100140B (en) 2022-07-27
CA3103160C (en) 2023-03-07
IL279593A (en) 2021-03-01
JP2021528383A (ja) 2021-10-21
CA3103160A1 (en) 2020-01-02
CN112351985B (zh) 2023-12-15
WO2020004938A1 (en) 2020-01-02
BR112020026641A2 (pt) 2021-03-30
NZ770629A (en) 2024-07-26
KR20210014212A (ko) 2021-02-08
JP7200453B2 (ja) 2023-01-10
US20210275532A1 (en) 2021-09-09
EA202190125A1 (ru) 2021-05-24
AU2019292207B2 (en) 2022-06-30
EP3814350A1 (en) 2021-05-05
KR102698500B1 (ko) 2024-08-26
AU2019292207A1 (en) 2021-02-18
EP3814350A4 (en) 2022-05-04
SG11202013029UA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
JOP20200081A1 (ar) أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2018003491A (es) Represores de htt y usos de estos.
UY35500A (es) Indazoles sustituidos con heteroarilo
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201690844A1 (ru) Ингибиторы gsk-3
DOP2016000120A (es) Nuevos inhibidores de dgat2
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX377663B (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
UY37551A (es) Activador de nrf2
CL2021000797A1 (es) Una ayuda para la deposición de fluidos agrícolas.